On September 16, 2020 Beijing-based Biocytogen reported that it completed a $142 million Series D+ round led by returning investor CMB International (Press release, Biocytogen, SEP 16, 2020, View Source [SID1234565242]). Biocytogen is a CRO that provides gene-modified animal models for drug discovery and preclinical testing . Founded in 2008, Biocytogen has branches in Beijing, Haimen /Jiangsu, Shanghai and Boston. The company generates custom gene-modified animal models/cell lines used for immunoncology molecules and therapeutic antibodies. One year ago, Biocytogen closed a $77 million Series D venture round.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!